InvestSMART

Nova Eye Medical Limited (ASX:EYE)

ALERT: Price-sensitive ASX Announcement for EYE
Current share price for EYE : $0.130 0.005 (4%)+
Announcement
Release
5 May 2026 9:48AM
Price at Release
$0.125
Full Release
download
Summary
Nova Eye Medical Limited has reported a record monthly sales figure in the USA for April 2026, surpassing their March 2026 record. This achievement contributed to a trailing twelve-month sales figure of US$22.8 million, marking a 26% increase over the prior year, with sales excluding China amounting to US$21.6 million. As a result, the company has raised its FY26 sales guidance to between US$22 million and US$23 million. Nova Eye Medical also noted its first positive EBITDA from Operations of US$138,000 for the third quarter of FY26, driven by a compound quarterly sales growth rate in the U.S., which forms a significant part of their revenue. The favorable trading conditions in the U.S. interventional glaucoma sector, which constitutes a large portion of global market revenue, have further supported this growth.
Key Points
  • Nova Eye Medical Limited announced a new monthly sales record in the USA in April 2026.
  • Trailing twelve-month sales, excluding China, reached US$21.6 million, up 27% on the prior period.
  • Group trailing twelve-month sales amounted to US$22.8 million, up 26% on the prior comparative period.
  • The company upgraded its FY26 sales guidance to US$22–23 million, excluding China.
  • The first reported positive EBITDA from Operations was US$138,000 for Q3 FY26.
  • The U.S. market accounts for approximately 53% of global market revenue, growing at 8% per annum.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.